BANK VONTOBEL/CALL/MODERNA/84/1/21.06.24 | Market Closed - Euronext Paris 12:30:01 2024-06-20 pm EDT | ||
| 4.61 EUR | +2.79% |
|
| Current month | -15.41% | ||
| 1 month | -12.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 4.61 | +2.79% |
| 24-06-19 | 4.485 | -4.98% |
| 24-06-18 | 4.72 | -8.88% |
| 24-06-17 | 5.18 | -0.38% |
| 24-06-14 | 5.2 | -10.34% |
Real-time Euronext Paris
Last update June 20, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| KM19V | |
| ISIN | DE000VM3U713 |
| Date issued | 2023-10-20 |
| Strike | 84 $ |
| Maturity | Today (1 Days) |
| Parity | 1 : 1 |
| Emission price | 1.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.97 € |
|---|---|
| Lowest since issue | 0.745 € |
| Spread | 0.02 € |
| Spread % | 0.43% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
134.4
USD
Average target price
145.2
USD
Spread / Average Target
+8.05%
- Stock Market
- Warrants
- KM19V Warrant
